RU2013156435A - Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения - Google Patents
Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения Download PDFInfo
- Publication number
- RU2013156435A RU2013156435A RU2013156435/10A RU2013156435A RU2013156435A RU 2013156435 A RU2013156435 A RU 2013156435A RU 2013156435/10 A RU2013156435/10 A RU 2013156435/10A RU 2013156435 A RU2013156435 A RU 2013156435A RU 2013156435 A RU2013156435 A RU 2013156435A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- cell
- synergistic combination
- lymphoma
- leukemia
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 claims abstract 20
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract 13
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract 11
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims abstract 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract 6
- 206010025323 Lymphomas Diseases 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims abstract 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 208000032839 leukemia Diseases 0.000 claims abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims abstract 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000017604 Hodgkin disease Diseases 0.000 claims abstract 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract 2
- 201000002481 Myositis Diseases 0.000 claims abstract 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims abstract 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 2
- 230000001684 chronic effect Effects 0.000 claims abstract 2
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims abstract 2
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract 2
- 201000008383 nephritis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000015163 Biliary Tract disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000006473 polyradiculopathy Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504744P | 2011-07-06 | 2011-07-06 | |
| US61/504,744 | 2011-07-06 | ||
| EP11172865 | 2011-07-06 | ||
| EP11172865.5 | 2011-07-06 | ||
| PCT/EP2012/063207 WO2013004806A1 (en) | 2011-07-06 | 2012-07-06 | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013156435A true RU2013156435A (ru) | 2015-08-20 |
Family
ID=47436548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013156435/10A RU2013156435A (ru) | 2011-07-06 | 2012-07-06 | Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140234298A1 (enExample) |
| EP (1) | EP2729498A1 (enExample) |
| JP (1) | JP2014520784A (enExample) |
| KR (1) | KR20140061379A (enExample) |
| CN (1) | CN103827143A (enExample) |
| AU (2) | AU2012280267B2 (enExample) |
| BR (1) | BR112013033944A2 (enExample) |
| CA (1) | CA2839513A1 (enExample) |
| RU (1) | RU2013156435A (enExample) |
| WO (1) | WO2013004806A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109999195A (zh) | 2012-09-20 | 2019-07-12 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| MX2017016651A (es) * | 2015-06-24 | 2018-05-14 | Hoffmann La Roche | Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias. |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| US20190218284A1 (en) * | 2016-09-01 | 2019-07-18 | The Regents Of The University Of Colorado A Body Corporate | Methods of treating eosinophilic gastrointestinal diseases |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US11673962B2 (en) | 2017-10-02 | 2023-06-13 | Humanigen, Inc. | Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN112805301B (zh) | 2018-10-15 | 2023-07-21 | 安立玺荣生医(香港)有限公司 | 粒细胞-巨噬细胞集落刺激因子的抗体及其用途 |
| CA3116412A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| KR20210090211A (ko) * | 2018-11-09 | 2021-07-19 | 키닉사 파마슈티컬스, 리미티드 | 거대 세포 동맥염에 대한 치료 |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| US20220202967A1 (en) * | 2019-04-25 | 2022-06-30 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| KR20230095983A (ko) * | 2020-10-26 | 2023-06-29 | 키닉사 파마슈티컬스, 리미티드 | Gm-csf 길항제를 사용한 암의 치료 |
| JP7651145B2 (ja) * | 2021-04-20 | 2025-03-26 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 向上した癌細胞死滅効能を有する非対称抗体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1005870B1 (en) * | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| EP2289543A1 (en) | 1998-11-09 | 2011-03-02 | Biogen Idec Inc. | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| US7115261B1 (en) | 1999-02-12 | 2006-10-03 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| ATE444308T1 (de) | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| EA013162B1 (ru) | 2005-04-18 | 2010-02-26 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
| BRPI0610796B8 (pt) * | 2005-05-18 | 2021-05-25 | Morphosys Ag | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo |
| CN101223448B (zh) * | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| CN101501070B (zh) * | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
| NZ598345A (en) * | 2006-11-21 | 2013-09-27 | Kalobios Pharmaceuticals Inc | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| CN101687926A (zh) | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| WO2008153997A1 (en) * | 2007-06-07 | 2008-12-18 | Brookwood Pharmaceuticals, Inc. | Reduced-mass, long-acting dosage forms |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| EP2217626A4 (en) | 2007-11-12 | 2011-06-22 | Crc For Asthma And Airways Ltd | EPITOP FOR NEUTRALIZING ANTIBODIES |
| TWI434854B (zh) | 2007-11-13 | 2014-04-21 | Evec Inc | 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物 |
| JP5688363B2 (ja) | 2008-04-28 | 2015-03-25 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 顆粒球−マクロファージコロニー刺激因子に対する抗体 |
| EP2279001B1 (en) | 2008-04-29 | 2015-09-30 | Amgen Research (Munich) GmbH | Inhibitors of gm-csf and il-17 for therapy |
| US20100122819A1 (en) | 2008-11-17 | 2010-05-20 | Baker Hughes Incorporated | Inserts with Swellable Elastomer Seals for Side Pocket Mandrels |
| CN102439163A (zh) * | 2009-02-16 | 2012-05-02 | 拜奥雷克斯治疗公司 | 人源化抗cd20抗体及使用方法 |
| US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
| SG175305A1 (en) | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
-
2012
- 2012-07-06 KR KR1020147003186A patent/KR20140061379A/ko not_active Withdrawn
- 2012-07-06 US US14/130,667 patent/US20140234298A1/en not_active Abandoned
- 2012-07-06 CN CN201280033421.3A patent/CN103827143A/zh active Pending
- 2012-07-06 EP EP12735498.3A patent/EP2729498A1/en not_active Withdrawn
- 2012-07-06 AU AU2012280267A patent/AU2012280267B2/en not_active Ceased
- 2012-07-06 CA CA2839513A patent/CA2839513A1/en not_active Abandoned
- 2012-07-06 JP JP2014517813A patent/JP2014520784A/ja active Pending
- 2012-07-06 RU RU2013156435/10A patent/RU2013156435A/ru not_active Application Discontinuation
- 2012-07-06 WO PCT/EP2012/063207 patent/WO2013004806A1/en not_active Ceased
- 2012-07-06 BR BR112013033944A patent/BR112013033944A2/pt not_active IP Right Cessation
-
2016
- 2016-03-18 AU AU2016201736A patent/AU2016201736A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012280267A1 (en) | 2014-01-16 |
| CN103827143A (zh) | 2014-05-28 |
| US20140234298A1 (en) | 2014-08-21 |
| JP2014520784A (ja) | 2014-08-25 |
| BR112013033944A2 (pt) | 2017-12-19 |
| WO2013004806A1 (en) | 2013-01-10 |
| CA2839513A1 (en) | 2013-01-10 |
| AU2012280267B2 (en) | 2016-04-21 |
| KR20140061379A (ko) | 2014-05-21 |
| AU2016201736A1 (en) | 2016-04-07 |
| EP2729498A1 (en) | 2014-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013156435A (ru) | Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения | |
| JP2014520784A5 (enExample) | ||
| Hiepe et al. | Plasma cells as an innovative target in autoimmune disease with renal manifestations | |
| RU2476441C2 (ru) | Cd19-связывающие средства и их применение | |
| FI3778641T3 (fi) | Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2018513149A5 (enExample) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| Levesque | Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2011516084A5 (enExample) | ||
| MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| RU2014133363A (ru) | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством | |
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| JP2013542194A5 (enExample) | ||
| NZ714482A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| RU2013145243A (ru) | Гуманизированные антитела к ctla4 | |
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| JP2017515815A5 (enExample) | ||
| JP2017528462A5 (enExample) | ||
| RU2012138703A (ru) | Терапевтические и диагностические способы с применением анти-cd200 антител | |
| RU2010143454A (ru) | Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения не-ходжкинских лимфом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161026 |